anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
On Day 1, the project coordinator will explain the study to participants and answer any questions he/she may have. Those who agree to participate in the study will provide consent at the clinic and will also be asked to complete a questionnaire on an iPad in a small, private room at the clinic. The participant will complete the questionnaire alone, however, the project coordinator will read questions aloud if the participant chooses. Before leaving on Day 1, participants will fitted with a blood pressure monitor to be worn for the next 24 hours.

The clinical intervention portion of the study occurs during the morning of Day 2 (between 9:00 AM and 11:00 AM). Participants will be instructed to bring the blood pressure monitor and a list of current medications (or the actual medications) with them. First, participants will provide a urine sample and undergo blood pressure testing. A research nurse will insert a catheter (a small thin tube) into the participant's vein, and allow a 30-minute resting period so that the participant gets used to the catheter, and then take a baseline blood draw. Participants will judge how distressed they feel in that moment using a standard scale and tell the project coordinator his/her rating. Next, participants will be randomized to one of two study arms such that half will recall the racial experience and half will recall the non-racialized stressful event. An audience of two observers of same race will wear white coats and watch as the participants recall the stressful events. The research nurse will draw blood and take blood pressure measurements at multiple time points during both recall experiences. Immediately before and after each recall task, the participant will again judge how distressed he/she is feeling in that moment using the same scale as before. The project coordinator will explain the purpose of the story recall and common ways that individuals may respond to the task (such as feeling anxious after the task). A total of 100 people will take part in this study.
PURPOSE OF REVIEW: Sleep is an important component of cardiovascular (CV) health. This review summarizes the complex relationship between sleep and CV disease (CVD). Additionally, we describe the data supporting the treatment of sleep disturbances in preventing and treating CVD.
RECENT FINDINGS: Recent guidelines recommend screening for obstructive sleep apnea in patients with atrial fibrillation. New data continues to demonstrate the importance of sleep quality and duration for CV health. There is a complex bidirectional relationship between sleep health and CVD. Sleep disturbances have systemic effects that contribute to the development of CVD, including hypertension, coronary artery disease, heart failure, and arrhythmias. Additionally, CVD contributes to the development of sleep disturbances. However, more data are needed to support the role of screening for and treatment of sleep disorders for the prevention of CVD.
Ovarian cancer is the malignant tumor with the highest mortality rate among women, and also the most intractable gynecological malignant tumor in clinical treatment. Its incidence rate and mortality are increasing year by year. China's incidence rate of ovarian cancer ranks first in the world.Due to the lack of typical clinical symptoms and effective screening tools in the early stage, more than 70% of patients were in advanced cancer when diagnosed,that is, there was peritoneal and/or distant metastasis. The mortality rate was high (mortality/incidence rate ratio was 60%) , the radical cure rate was low, and the 5-year overall survival rate was only 30% . The survival rate of ovarian cancer is closely related to staging (stage I 5-year survival rate is 92%, stage IV is 5%) . Therefore, early and accurate detection and staging are of great significance for the selection of treatment methods and the improvement of patient survival rate.Positron emission tomography (PET) is a non-invasive molecular imaging technique. Currently, 18F-FDG PET/CT has been included as a routine examination in the postoperative evaluation of the NCCN ovarian cancer diagnosis and treatment guidelines as a supplementary examination method for preoperative evaluation. Therefore, 18F-FDG PET/CT is recommended by NCCN as an imaging biomarker for ovarian cancer, and performs well in early diagnosis, treatment planning, and postoperative evaluation. However, FDG PET/CT also has some limitations, such as its sensitivity being influenced by different histological subtypes (such as ovarian mucinous carcinoma, clear cell carcinoma, or low-grade serous carcinoma). In addition, false negatives caused by physiological high uptake in the intestine and false positives caused by ovarian physiological uptake and some benign lesions (such as cystadenoma, endometrioma, and acute inflammatory processes) still exist. Therefore, a more effective imaging technique is needed to improve the detection and staging of ovarian tumors.

α V β 3-Integrins play a crucial role in promoting and maintaining angiogenesis, and have been identified as biomarkers of angiogenesis. Research has found that integrins α V β 3 is highly expressed in neovascular endothelial cells and tumor cells, including ovarian cancer, and plays an important role in regulating tumor growth, angiogenesis, local invasion, and metastasis potential.Research has shown that 68 Ga-FAPI-04 is a novel radioligand targeting fibroblast activating protein (FAP), which has recently been used for tumor microenvironment imaging, especially cancer associated fibroblasts (CAFs), with promising imaging results . Research has shown that compared to 18F-FDG, 68Ga-FAPI PET/CT has higher sensitivity in detecting and diagnosing lymph node and peritoneal metastases in ovarian cancer.
The treatment protocol is ART combined with pegylated interferon α-2b injection. The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week. Follow-up times are at baseline, and during treatment at weeks 4, 8, 12, 24, 36, 48, 60, and 72.
Background and Objectives: Acute kidney injury (AKI) remains a significant complication following major cardiac surgery. Marinobufagenin (MBG), a cardiotonic steroid involved in sodium balance and blood pressure regulation, has been linked to organ damage after ischemia-reperfusion events. This pilot, prospective study investigates the utility of circulating MBG to improve AKI risk assessment in cardiac surgery patients as a stand-alone biomarker and after inclusion in a validated risk model (STS-AKI score). Materials and Methods: We included 45 patients undergoing elective cardiac surgery. The MBG levels were measured preoperatively and at 4, 8, and 12 h post-surgery. The AKI was defined according to the KDIGO guidelines. Statistical analyses assessed the diagnostic and prognostic utility of MBG and its integration with the STS-AKI score. Results: An AKI occurred in 26.7% of the patients. The STS-AKI score performed well in this cohort (AUC: 0.736). The MBG levels displayed a decreasing trend in the whole population after surgery (p = 0.02). However, in the AKI patients, MBG increased at 4 and 8 h before decreasing at 12 h post-surgery. The MBG changes from the baseline to 8 h and from 8 to 12 h post-surgery showed a remarkable diagnostic accuracy for an AKI (AUCs: 0.917 and 0.843, respectively). Integrating these MBG changes with the STS-AKI score significantly improved the model performance, including discrimination, calibration, and risk reclassification. Conclusions: The MBG measurement, particularly any dynamic changes post-surgery, enhances AKI risk stratification in cardiac surgery patients. Integrating MBG with the STS-AKI score offers more accurate risk predictions, potentially leading to better patient management and outcomes.
FIELD: face skin care means. SUBSTANCE: mask has substrate, animal protein, mineral salts and biologically active substances of animal and plant origin. Mask is supplemented with amino acid vitamin complex of nutrient medium for animal cell cultures, such as Igla medium, sodium benzoate and flavor. Polyethylene oxide gel is used as substrate, egg albumen as animal protein, balanced Henx solution salt compound as mineral salts, propolis extract is used as biologically active substance of animal origin and lemon juice, mountain ash extract and marigold infusion as biologically active substance of plant origin. Mentioned components are taken in the following ratio, wt. -%: egg albumen, 5.0-20.0; balanced Henx salt solution, 0.5-3.0; sodium bensoate, 0.07-0.2; lemon juice, 1.0-5.0; amino acid vitamin complex of Igla medium, 0.007-0.05; mountain ash extract, 0.1-1.0; propolis extract, 5.0-10.0; marigold infusion, 0.3-1.2; flavor, 0.1-0.2; polyethylene oxide, the balance. EFFECT: increased efficiency in cleaning face skin without removal of active substances from skin cells.
BACKGROUND: Tibetan medicine Gaoyuan'an capsule (GYAC) is widely used to prevent pulmonary edema at high altitude, but the specific mechanism has not been explored. In this study, we analyzed the mechanism of GYAC in hypoxia tolerance, and provided a new idea for the prevention and treatment of altitude disease.
METHODS: The effective components and corresponding targets of GYAC were screened out by the Chinese herbal medicine network database, and the key targets of hypoxia tolerance were retrieved by Genecards, OMIM and PubMed database. Cytoscape 3.7.2 was used to construct GYAC ingredient-target-hypoxia tolerance-related target network. GO function annotation and KEGG enrichment analysis were performed to predict the pathways in which target genes may be involved, and molecular docking was used to verify the binding ability of the compound to target genes. In vitro, the above results were further verified by molecular experiment.
RESULTS: We found that GYAC can improve hypoxia tolerance by regulating various target genes, including IL6, IFNG, etc. The main regulatory pathways were HIF-1 signaling pathway. Molecular docking showed that the affinity between luteolin and target genes (IL6, IFNG) were better. In vitro, we observed that hypoxia can inhibit cell viability and promote apoptosis of H9C2 cell. And hypoxia can promote the expression of LDH. After the addition of luteolin, the decrease of cell viability, the increase of cell apoptosis, LDH release and the decrease of mitochondrial membrane potential were inhibited. Besides, inflammatory related factors (IL-6, IL-10, IL-2, IFNG and VEGFA) expression were also inhibited hypoxic cell models.
CONCLUSIONS: The results of network pharmacology and molecular docking showed that luteolin, a monomeric component of GYAC, played a role in hypoxia tolerance through a variety of target genes, such as IL6, IFNG. What's more, we have discovered that luteolin can reduce the inflammatory response in cardiac myocytes, thereby alleviating mitochondrial damage, and ultimately enhancing the hypoxia tolerance of H9C2 cardiomyocytes.
FIELD: medicine; methods for extraction of arabinogalactane from larch wood. SUBSTANCE: method for extraction of arabinogalactane consists in that larch wood sawdust is subjected to extraction at ambient temperature with water (raw material-to-extracting agent ratio of (1:5)-(107) for 1.5 h. Filtered aqueous extract is boiled down to one half of the initial volume, cooled and with continuous stirring is added with one and one half volume of acetone with addition of 0.2-0.39 of sodium chloride (of aqueous extract). Decanted from arabinogalactane easily precipitated is supernatant liquid and arabinogalactane sediment is washed with acetone and dried. The offered method allows simple production from larch wood of arabinogalactane of high purity degree due to exclusion from the process of the stage of oxidation of phenol impurities and heating during precipitation. Duration of the process is reduced from 30 h according to that of the prototype down to 5.25 h with preserved quality of arabinogalactane. EFFECT: simplified method for extraction of arabinogalactane with preserved high purity degree of the product.
Telehealth delivery of cardiac rehabilitation via Second Life virtual world platform. 12-week, home-based program.
BACKGROUND: Three-dimensional (3D) chromatin architecture frequently altered in cancer. However, its changes during the pathogenesis of hepatocellular carcinoma (HCC) remained elusive.
METHODS: Hi-C and RNA-seq were applied to study the 3D chromatin landscapes and gene expression of HCC and ANHT. Hi-C Pro was used to generate genome-wide raw interaction matrices, which were normalized via iterative correction (ICE). Moreover, the chromosomes were divided into different compartments according to the first principal component (E1). Furthermore, topologically associated domains (TADs) were visualized via WashU Epigenome Browser. Furthermore, differential expression analysis of ANHT and HCC was performed using the DESeq2 R package. Additionally, dysregulated genes associated with 3D genome architecture altered were confirmed using TCGA, qRT-PCR, immunohistochemistry (IHC), etc. RESULTS: First, the intrachromosomal interactions of chr1, chr2, chr5, and chr11 were significantly different, and the interchromosomal interactions of chr4-chr10, chr13-chr21, chr15-chr22, and chr16-chr19 are remarkably different between ANHT and HCC, which resulted in the up-regulation of TP53I3 and ZNF738 and the down-regulation of APOC3 and APOA5 in HCC. Second, 49 compartment regions on 18 chromosomes have significantly switched (A-B or B-A) during HCC tumorigenesis, contributing to up-regulation of RAP2A. Finally, a tumor-specific TAD boundary located on chr5: 6271000-6478000 and enhancer hijacking were identified in HCC tissues, potentially associated with the elevated expression of MED10, whose expression were associated with poor prognosis of HCC patients.
CONCLUSION: This study demonstrates the crucial role of chromosomal structure variation in HCC oncogenesis and potential novel biomarkers of HCC, laying a foundation for cancer precision medicine development.
The invention discloses a new Chinese medicine composite for treatment of acute gastroenteritis and a preparation method thereof. The Chinese medicine composite of the invention mainly comprises the following materials of tuckahoe, magnolia officinalis, rhizoma atractylodis macrocephalae, plantain seed, dried ginger, rhizoma pinelliae, styrax, medicated leaven, fructus hordei germinatus, semen arecae prepareta, endothelium corneum gigeriae galli, rhizoma corydalis, medicinal evodia fruit, cassia, fructus quisqualis, pericarpium citri reticulatae, rhizoma coptidis, oriental water plantain rhizome, cortex periplocae radicis, taraxacum, bunge corydalis herb , pollen typhae carbonisatus, honeysuckle flower, jobstears seed, and the like. The Chinese medicine composite of the invention can be prepared into any common oral preparation according to the conventional Chinese medicine preparation method. The composite can obviously improve nausea, emesis, abdominal pain, diarrhea, fever, and thelike. The serious patient may have symptoms of dehydration, electrolyte disturbance, shock bowel, septicemia and the like. The composite has reliable and apparent clinical effect and fast desired effect. Due to the combination of the medicines both as food and medicine according to state-promulgated pharmacopoeia, the Chinese medicine composite of the invention has the advantages of low cost and no toxic and side effect basically.
The invention relates to a preparation method of an in vivo glycation level-improving dementia animal model. By dosing animals with D-ribose, the invention provides an in vivo glycation level-improving dementia animal model and its preparation method. The animal model provided in the invention has the characteristics of normal blood sugar level, enhanced glycation level, and damaged spatial learning and memory ability. At the same time, the method disclosed in the invention has the advantages of simplicity, practicability, easy control, stability and good reproducibility, low model making cost as well as short model making cycle. The model making method provided in the invention can be used for qualitative and quantitative analysis, pathomorphological contrastive analysis, and also can be used for statistical treatment and analysis. Also, the method can be used for studying in vivo glycation level enhancement-caused related diseases and the pathogenesis of neurodegenerative diseases, as well as studying and evaluating related disease treatment methods.
Resistance training in group, with one instructor. This pre-choreographed class contains 10 to 12 exercises with a barbell, weights and a step. Number of repetitions throughout the class varies between muscle groups, but is generally high (20-100).
The invention relates to a seclenic acid I from penicillium oxalicum and application thereof in preparing a human esophageal cancer resistant medicament. The compound has effect in inhibiting proliferation of human esophageal cancer cell. The structural formula is as follows: . Culturing Penicillium oxalicum ( Penicillium oxalicum ) IBPT-6, obtaining a fermentation product, and separating and purifying the compound from the fermentation product. Experiments prove that the compound has better anti-tumor activity on human esophageal cancer cells EC 9706. Can be used for preparing human esophageal cancer cell proliferation inhibition drugs or antitumor drugs for human esophageal cancer research.
A number of differences in pediatric cardiac catheterization procedures exist that limit the transferability of research findings from the adult literature. For example, the majority of pediatric cardiac catheterizations are performed under general anesthetic, and femoral sheaths are removed while under general anesthetic and at the end of the procedure. In contrast in adult clinical practice, procedures are not performed under general anesthetic, and femoral sheaths are removed when patients are awake and often 4 to 6 hours after the end of the procedure. These differences limit the ability to apply research findings in adults to pediatrics, warranting further study of the effects of local anesthetic on femoral site pain in children. As well, studies in adults have examined pain only up to 20 minutes after sheath removal. We seek to investigate the impact of bupivacaine up to 6 hours after cardiac catheterization in children.
RATIONALE AND OBJECTIVES: The use of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) in assessing inflammatory diseases has shown significant promise. Uptake patterns in perianal fistulas, which may be an incidental finding on PET/CT, have not been purposefully studied. Our aim was to compare FDG uptake of perianal fistulas to that of the liver and anal canal in patients who underwent PET/CT for hematologic/oncologic diagnosis or staging.
MATERIALS AND METHODS: We retrospectively identified patients who underwent FDG-PET/CT imaging between January 2011 and May 2023, where the report described a perianal fistula or abscess. PET/CTs of patients included in the study were retrospectively analyzed to record the maximum standardized uptake value (SUVmax) of the fistula, abscess, anal canal, rectum, and liver. Fistula-to-liver and Fistula-to-anus SUVmax ratios were calculated. We statistically compared FDG activity among the fistula, liver, and anal canal. We also assessed FDG activity in patients with vs. without anorectal cancer, as well as across different St. James fistula grades.
RESULTS: The study included 24 patients with identifiable fistulas. Fistula SUVmax (mean=10.8 ± 5.28) was significantly higher than both the liver (mean=3.09 ± 0.584, p < 0.0001) and the anal canal (mean=5.98 ± 2.63, p = 0.0005). Abscess fistula SUVmax was 15.8 ± 4.91. St. James grade 1 fistulas had significantly lower SUVmax compared to grades 2 and 4 (p = 0.0224 and p = 0.0295, respectively). No significant differences existed in SUVmax ratios between anorectal and non-anorectal cancer groups.
CONCLUSION: Perianal fistulas have increased FDG avidity with fistula SUVmax values that are significantly higher than the anal canal.
A search of a safety surveillance database revealed a total of eighteen cases of tizanidine overdose. Of the fourteen intentional overdoses, five have resulted in fatality, and in at least three of these cases, other CNS depressants were involved. One fatality was secondary to pneumonia and sepsis, which were sequelae of the ingestion. The majority of cases involve depressed consciousness (somnolence, stupor or coma), depressed cardiovascular function (bradycardia, hypotension) and depressed respiratory function (respiratory depression or failure).

Should overdose occur, basic steps to ensure the adequacy of an airway and the monitoring of cardiovascular and respiratory systems should be undertaken. In general, symptoms resolve within one to three days following discontinuation of tizanidine and administration of appropriate therapy. Due to the similar mechanism of action, symptoms and management of tizanidine overdose are similar to those following clonidine overdose. For the most recent information concerning the management of overdose, contact a poison control center.
Recent studies have revealed a robust link between attentional ability and resilience against stress-related psychopathology, in general, and against alcohol use disorder (AUD) specifically. For example, self-reported attentional ability correlates with scales of psychological resilience and with lower alcohol misuse in at-risk individuals. One mechanism by which attention may relate to resilience in AUD is through its effects on alcohol cue reactivity. Exposure to alcohol cues can induce motivation to drink alcohol for those with AUD. Leveraging the high rates of co-morbidity of AUD and attention-deficit/hyperactivity disorder, this pilot study seeks to demonstrate whether experimentally enhancing attention in individuals with both AUD and attentional deficits associated with attention-deficit/hyperactivity disorder (ADHD) reduces markers of addiction severity (i.e., craving and attentional bias responses to alcohol cues) and will explore the neural and behavioral mechanisms. Methylphenidate not only improves sustained attention, but in users of cocaine and methamphetamine, it was previously shown to reduce craving, attentional bias, and neural responses to viewing drug-related cues. Here we will use this commonly-prescribed medication as a pharmacological probe of attentional processes related to alcohol use disorder. We hypothesize that acute methylphenidate-associated attentional enhancement will engage compensatory brain mechanisms that will lead to attenuated craving, reduced attentional bias, and modulated neural responses to alcohol cues in young adults with AUD and ADHD. Thirty young adults with AUD and ADHD will be recruited for a double-blind, placebo-controlled, within-subjects experiment to test the effects of an acute 20 mg MPH administration to increase attention on cue-induced alcohol craving \[during simultaneous functional magnetic resonance imaging (fMRI) and EEG\] and attentional bias. Subjects will also perform computerized tasks of general attention with non-alcohol-related stimuli. The goal of this project is to support the design and funding proposal of a larger study.